Intraocular bevacizumab should be considered as a potential cause of reversible left ventricular systolic dysfunction mimicking stress-induced cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to possible bevacizumab-related cardiomyopathy; single case leaves open causality pending confirmation.
Heart failure has been reported as a rare side effect of bevacizumab, a chemotherapeutic agent, used in the treatment of breast cancer. However, reversible left ventricular systolic dysfunction with a pattern similar to stress-induced cardiomyopathy has not been reported. The etiopathogenesis of stress-induced cardiomyopathy is poorly understood. Given this uncertainty, we should always look out for other potential offenders causing similar presentation, rather than label all of them as "stress-induced".
No takes yet. Share an insight, caveat, or question.
Penumetsa et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: